Evidence map›Paper›PMID 36870034›Full record

ArticleInfection2023

Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.

Stefano Tancredi, Arnaud Chiolero, Cornelia Wagner, Moa Lina Haller, Patricia Chocano-Bedoya, Natalia Ortega, Nicolas Rodondi, Laurent Kaufmann, Elsa Lorthe, Hélène Baysson and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Stefano TancrediPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland. stefano.tancredi@unifr.ch.
Arnaud ChioleroPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland.
Cornelia WagnerPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland.
Moa Lina HallerInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Patricia Chocano-BedoyaPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland.
Natalia OrtegaPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland.
Nicolas RodondiInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Laurent KaufmannCantonal Public Health Service of the Canton of Neuchâtel, Neuchâtel, Switzerland.
Elsa LortheUnit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Hélène BayssonUnit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Silvia StringhiniUnit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Gisela MichelDepartment Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Chantal LüdiDepartment Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Erika HarjuDepartment Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Irene FrankClinical Trial Unit, Lucerne Cantonal Hospital, Lucerne, Switzerland.
Medea ImbodenSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Melissa WitzigSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Dirk KeidelSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Nicole Probst-HenschSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Rebecca AmatiInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Emiliano AlbaneseInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Laurie CornaDepartment of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland.
Luca CrivelliDepartment of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland.
Julia VincentiniCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Semira Gonseth NussléCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Murielle BochudCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Valérie D'AcremontSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Philipp KohlerDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Christian R KahlertDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Alexia CusiniDivision of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland.
Anja FreiEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Milo A PuhanEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Marco GeiggesEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Marco KaufmannEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Jan FehrEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Stéphane CullatiPopulation Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland.
Corona Immunitas Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to assess the seroprevalence trends of SARS-CoV-2 antibodies in several Swiss cantons between May 2020 and September 2021 and investigate risk factors for seropositivity and their changes over time.

methodsWe conducted repeated population-based serological studies in different Swiss regions using a common methodology. We defined three study periods: May-October 2020 (period 1, prior to vaccination), November 2020-mid-May 2021 (period 2, first months of the vaccination campaign), and mid-May-September 2021 (period 3, a large share of the population vaccinated). We measured anti-spike IgG. Participants provided information on sociodemographic and socioeconomic characteristics, health status, and adherence to preventive measures. We estimated seroprevalence with a Bayesian logistic regression model and the association between risk factors and seropositivity with Poisson models.

resultsWe included 13,291 participants aged 20 and older from 11 Swiss cantons. Seroprevalence was 3.7% (95% CI 2.1-4.9) in period 1, 16.2% (95% CI 14.4-17.5) in period 2, and 72.0% (95% CI 70.3-73.8) in period 3, with regional variations. In period 1, younger age (20-64) was the only factor associated with higher seropositivity. In period 3, being aged ≥ 65 years, with a high income, retired, overweight or obese or with other comorbidities, was associated with higher seropositivity. These associations disappeared after adjusting for vaccination status. Seropositivity was lower in participants with lower adherence to preventive measures, due to a lower vaccination uptake.

conclusionsSeroprevalence sharply increased over time, also thanks to vaccination, with some regional variations. After the vaccination campaign, no differences between subgroups were observed.

Indexed as

COVID-19Antibodies, ViralBayes TheoremHumansSARS-CoV-2Seroepidemiologic StudiesAntibodies, ViralCOVID-19 pandemicEpidemiologyPublic healthSARS-CoV-2SeroprevalenceSurveillance

Identifiers

PMID36870034
PMCPMC9985433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.